RU2011119848A - METHOD FOR PREVENTION OF SPIKE EDUCATION - Google Patents

METHOD FOR PREVENTION OF SPIKE EDUCATION Download PDF

Info

Publication number
RU2011119848A
RU2011119848A RU2011119848/15A RU2011119848A RU2011119848A RU 2011119848 A RU2011119848 A RU 2011119848A RU 2011119848/15 A RU2011119848/15 A RU 2011119848/15A RU 2011119848 A RU2011119848 A RU 2011119848A RU 2011119848 A RU2011119848 A RU 2011119848A
Authority
RU
Russia
Prior art keywords
map kinase
blocker
administered
serous cavity
prevention
Prior art date
Application number
RU2011119848/15A
Other languages
Russian (ru)
Inventor
Михаил Геннадьевич Шурыгин
Ирина Александровна Шурыгина
Евгений Георгиевич Григорьев
Наталья Ильинична Аюшинова
Original Assignee
Открытое Акционерное Общество "Фармасинтез"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Открытое Акционерное Общество "Фармасинтез" filed Critical Открытое Акционерное Общество "Фармасинтез"
Priority to RU2011119848/15A priority Critical patent/RU2011119848A/en
Priority to CA2836268A priority patent/CA2836268C/en
Priority to KR1020137033587A priority patent/KR20140074259A/en
Priority to RSP20191180 priority patent/RS59382B1/en
Priority to AU2012257347A priority patent/AU2012257347A1/en
Priority to RU2013155582/15A priority patent/RU2582975C2/en
Priority to PL12785811T priority patent/PL2716684T3/en
Priority to EA201301275A priority patent/EA025493B1/en
Priority to PCT/IB2012/052483 priority patent/WO2012156938A1/en
Priority to MX2013013409A priority patent/MX369019B/en
Priority to EP19176981.9A priority patent/EP3569636A1/en
Priority to CN201280023192.7A priority patent/CN103534293B/en
Priority to DK12785811.6T priority patent/DK2716684T3/en
Priority to SI201231662T priority patent/SI2716684T1/en
Priority to UAA201313464A priority patent/UA113733C2/en
Priority to GEAP201213326A priority patent/GEP201706614B/en
Priority to NZ618882A priority patent/NZ618882B2/en
Priority to AP2013007258A priority patent/AP3694A/en
Priority to JP2014510934A priority patent/JP5936683B2/en
Priority to PE2013002510A priority patent/PE20141161A1/en
Priority to EP12785811.6A priority patent/EP2716684B1/en
Priority to LTEP12785811.6T priority patent/LT2716684T/en
Priority to MYPI2014000195A priority patent/MY198042A/en
Priority to BR112013029616-0A priority patent/BR112013029616B1/en
Priority to KR1020177007939A priority patent/KR20170034950A/en
Publication of RU2011119848A publication Critical patent/RU2011119848A/en
Priority to IL229423A priority patent/IL229423B/en
Priority to ZA2013/08542A priority patent/ZA201308542B/en
Priority to NI201300124A priority patent/NI201300124A/en
Priority to DO2013000266A priority patent/DOP2013000266A/en
Priority to CR20130600A priority patent/CR20130600A/en
Priority to MX2019011386A priority patent/MX2019011386A/en
Priority to CO13269426A priority patent/CO6801779A2/en
Priority to SV2013004582A priority patent/SV2013004582A/en
Priority to US14/082,947 priority patent/US10172952B2/en
Priority to CU2013000154A priority patent/CU20130154A7/en
Priority to CL2013003305A priority patent/CL2013003305A1/en
Priority to MA36578A priority patent/MA35189B1/en
Priority to HK14101536.3A priority patent/HK1189012A1/en
Priority to AU2015213303A priority patent/AU2015213303A1/en
Priority to JP2016094386A priority patent/JP2016175931A/en
Priority to AU2017221883A priority patent/AU2017221883B2/en
Priority to US16/225,987 priority patent/US10493164B2/en
Priority to HRP20191638 priority patent/HRP20191638T1/en
Priority to CY20191100990T priority patent/CY1122190T1/en

Links

Abstract

1. Способ профилактики спайкообразования, включающий внутриполостное введение препарата, отличающийся тем, что вводят блокатор р38 MAP киназы.2. Способ по п.1, отличающийся тем, что в качестве блокатора р38 MAP киназы используют SB203580.3. Способ по п.1, отличающийся тем, что блокатор р38 MAP киназы вводят внутрь серозной полости однократно, непосредственно после завершения оперативного вмешательства, в виде стерильного раствора, в объеме, достаточном для смачивания всей поверхности серозной полости.4. Способ по п.1, отличающийся тем, что блокатор р38 MAP киназы вводят внутрь серозной полости в дозе, блокирующей не менее половины активности р38 MAP киназы в граничном слое клеток.1. A method for the prevention of adhesion formation, including intracavitary administration of the drug, characterized in that the p38 MAP kinase blocker is administered. The method according to claim 1, characterized in that SB203580.3 is used as a p38 MAP kinase blocker. The method according to claim 1, characterized in that the p38 MAP kinase blocker is administered once inside the serous cavity, immediately after completion of the surgical intervention, in the form of a sterile solution, in an amount sufficient to wet the entire surface of the serous cavity. The method according to claim 1, characterized in that the p38 MAP kinase blocker is administered inside the serous cavity at a dose blocking at least half of the p38 MAP kinase activity in the boundary layer of the cells.

Claims (4)

1. Способ профилактики спайкообразования, включающий внутриполостное введение препарата, отличающийся тем, что вводят блокатор р38 MAP киназы.1. A method for the prevention of adhesion formation, including intracavitary administration of the drug, characterized in that the p38 MAP kinase blocker is administered. 2. Способ по п.1, отличающийся тем, что в качестве блокатора р38 MAP киназы используют SB203580.2. The method according to claim 1, characterized in that SB203580 is used as a p38 MAP kinase blocker. 3. Способ по п.1, отличающийся тем, что блокатор р38 MAP киназы вводят внутрь серозной полости однократно, непосредственно после завершения оперативного вмешательства, в виде стерильного раствора, в объеме, достаточном для смачивания всей поверхности серозной полости.3. The method according to claim 1, characterized in that the p38 MAP kinase blocker is administered once inside the serous cavity, immediately after completion of the surgical intervention, in the form of a sterile solution, in an amount sufficient to wet the entire surface of the serous cavity. 4. Способ по п.1, отличающийся тем, что блокатор р38 MAP киназы вводят внутрь серозной полости в дозе, блокирующей не менее половины активности р38 MAP киназы в граничном слое клеток. 4. The method according to claim 1, characterized in that the p38 MAP kinase blocker is administered inside the serous cavity in a dose blocking at least half of the p38 MAP kinase activity in the boundary layer of cells.
RU2011119848/15A 2011-05-17 2011-05-17 METHOD FOR PREVENTION OF SPIKE EDUCATION RU2011119848A (en)

Priority Applications (44)

Application Number Priority Date Filing Date Title
RU2011119848/15A RU2011119848A (en) 2011-05-17 2011-05-17 METHOD FOR PREVENTION OF SPIKE EDUCATION
CN201280023192.7A CN103534293B (en) 2011-05-17 2012-05-17 The pharmaceutical composition relevant for the compound of adhesion treatment and prevention, compound and the method for prevention and therapy adhesion
MYPI2014000195A MY198042A (en) 2011-05-17 2012-05-17 Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
RSP20191180 RS59382B1 (en) 2011-05-17 2012-05-17 Compounds for the prophylaxis and treatment of the adhesion process
KR1020137033587A KR20140074259A (en) 2011-05-17 2012-05-17 Compounds for adhesion treatment and prevention, compound-related pharmaceutical compositions and methods for the prevention and treatment of adhesions
RU2013155582/15A RU2582975C2 (en) 2011-05-17 2012-05-17 Compounds, pharmaceutical compositions and method for prevention and treatment of adhesive process
PL12785811T PL2716684T3 (en) 2011-05-17 2012-05-17 Compounds for the prophylaxis and treatment of the adhesion process
EA201301275A EA025493B1 (en) 2011-05-17 2012-05-17 Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
PCT/IB2012/052483 WO2012156938A1 (en) 2011-05-17 2012-05-17 Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
MX2013013409A MX369019B (en) 2011-05-17 2012-05-17 Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process.
EP19176981.9A EP3569636A1 (en) 2011-05-17 2012-05-17 Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
LTEP12785811.6T LT2716684T (en) 2011-05-17 2012-05-17 Compounds for the prophylaxis and treatment of the adhesion process
DK12785811.6T DK2716684T3 (en) 2011-05-17 2012-05-17 RELATIONSHIPS FOR PREVENTION AND TREATMENT OF THE ADHESION PROCESS
BR112013029616-0A BR112013029616B1 (en) 2011-05-17 2012-05-17 P38 MAP KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION
UAA201313464A UA113733C2 (en) 2011-05-17 2012-05-17 COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SPYCHES, PHARMACEUTICAL COMPOSITIONS ON THEIR BASES AND THE METHOD OF PREVENTION AND TREATMENT OF SPYCHING
GEAP201213326A GEP201706614B (en) 2011-05-17 2012-05-17 Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
NZ618882A NZ618882B2 (en) 2011-05-17 2012-05-17 Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
AP2013007258A AP3694A (en) 2011-05-17 2012-05-17 Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
JP2014510934A JP5936683B2 (en) 2011-05-17 2012-05-17 Compounds, pharmaceutical compositions and methods for the treatment and prevention of adhesions
PE2013002510A PE20141161A1 (en) 2011-05-17 2012-05-17 THE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF ADHESION, THE PHARMACEUTICAL COMPOSITIONS RELATED TO THE COMPOUND AND THE METHODS FOR THE PREVENTION AND TREATMENT OF ADHESIONS
EP12785811.6A EP2716684B1 (en) 2011-05-17 2012-05-17 Compounds for the prophylaxis and treatment of the adhesion process
CA2836268A CA2836268C (en) 2011-05-17 2012-05-17 P38 map kinase inhibitor compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
AU2012257347A AU2012257347A1 (en) 2011-05-17 2012-05-17 Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
SI201231662T SI2716684T1 (en) 2011-05-17 2012-05-17 Compounds for the prophylaxis and treatment of the adhesion process
KR1020177007939A KR20170034950A (en) 2011-05-17 2012-05-17 p38 MAP kinase inhibitor compounds for the prophylaxis and treatment of adhesion process
ZA2013/08542A ZA201308542B (en) 2011-05-17 2013-11-13 Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
IL229423A IL229423B (en) 2011-05-17 2013-11-13 Compounds , pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
CO13269426A CO6801779A2 (en) 2011-05-17 2013-11-15 Compounds for the treatment and prevention of adhesion, pharmaceutical compositions related to the compound and methods for the prevention and treatment of adhesions
NI201300124A NI201300124A (en) 2011-05-17 2013-11-15 THE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF ADHESION, THE PHARMACEUTICAL COMPOSITIONS RELATED TO THE COMPOUND AND THE METHODS FOR THE PREVENTION AND TREATMENT OF ADHERENCES.
SV2013004582A SV2013004582A (en) 2011-05-17 2013-11-15 THE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF THE ACCESSION, THE PHARMACEUTICAL COMPOSITIONS RELATED TO THE COMPOUND AND THE METHODS FOR THE PREVENTION AND TREATMENT OF ADHERENCES
DO2013000266A DOP2013000266A (en) 2011-05-17 2013-11-15 COMPOUNDS FOR THE TREATMENT AND PREVENTION OF ADHERENCES, PHARMACEUTICAL COMPOSITIONS OF RELATED COMPOUNDS AND METHODS FOR THE TREATMENT AND PREVENTION OF ADHERENCES
CR20130600A CR20130600A (en) 2011-05-17 2013-11-15 THE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF THE ADHESION, THE PHARMACEUTICAL COMPOSITIONS RELATED TO THE COMPOUND AND THE METHODS FOR THE PREVENTION AND TREATMENT OF ADHERENCES
MX2019011386A MX2019011386A (en) 2011-05-17 2013-11-15 Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process.
CU2013000154A CU20130154A7 (en) 2011-05-17 2013-11-18 THE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF THE ACCESSION, THE PHARMACEUTICAL COMPOSITIONS RELATED TO THE COMPOUND AND THE METHODS FOR THE PREVENTION AND TREATMENT OF ADHERENCES
US14/082,947 US10172952B2 (en) 2011-05-17 2013-11-18 Compounds for adhesion treatment and prevention, compound-related pharmaceutical compositions and methods for the prevention and treatment of adhesions
CL2013003305A CL2013003305A1 (en) 2011-05-17 2013-11-18 Use of the compound 4-phenyl- (4-methylsulfinyl) -5- (4-pyridyl) -1h-imidazole, p38 map kinase inhibitors, to treat adhesions; compounds derived from 4-phenyl- (4-methylsulfinylphenyl) -5- (4-pyridyl) -1h-imodazole; and pharmaceutical compositions that comprise them.
MA36578A MA35189B1 (en) 2011-05-17 2013-12-17 Preparations, pharmaceutical compositions and method for preventing and treating the adhesion formation process
HK14101536.3A HK1189012A1 (en) 2011-05-17 2014-02-18 Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
AU2015213303A AU2015213303A1 (en) 2011-05-17 2015-08-12 Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
JP2016094386A JP2016175931A (en) 2011-05-17 2016-05-10 Methods for treating and preventing adhesion
AU2017221883A AU2017221883B2 (en) 2011-05-17 2017-09-01 Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
US16/225,987 US10493164B2 (en) 2011-05-17 2018-12-19 Method for preventing and treating adhesions
HRP20191638 HRP20191638T1 (en) 2011-05-17 2019-09-12 Compounds for the prophylaxis and treatment of the adhesion process
CY20191100990T CY1122190T1 (en) 2011-05-17 2019-09-20 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF THE ADHESION PROCESS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2011119848/15A RU2011119848A (en) 2011-05-17 2011-05-17 METHOD FOR PREVENTION OF SPIKE EDUCATION

Publications (1)

Publication Number Publication Date
RU2011119848A true RU2011119848A (en) 2012-11-27

Family

ID=49254499

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011119848/15A RU2011119848A (en) 2011-05-17 2011-05-17 METHOD FOR PREVENTION OF SPIKE EDUCATION

Country Status (4)

Country Link
CU (1) CU20130154A7 (en)
MY (1) MY198042A (en)
RU (1) RU2011119848A (en)
UA (1) UA113733C2 (en)

Also Published As

Publication number Publication date
UA113733C2 (en) 2017-03-10
MY198042A (en) 2023-07-27
CU20130154A7 (en) 2014-05-27

Similar Documents

Publication Publication Date Title
EA201491285A1 (en) IMPROVED COMPOSITIONS AND METHODS OF DELIVERY OF OMEPRAZOL AND ACETYLSALICYLIC ACID
EA201592250A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseases
EA201690223A1 (en) FACTOR INHIBITORS IN THE COMPLEMENT BASED ON PIPERIDININILINDOL DERIVATIVES AND THEIR APPLICATION
PH12014501277A1 (en) Kinase inhibitors
IN2014DN09434A (en)
EA201690287A1 (en) 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY
RU2013156378A (en) 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1h-benzimidazole-2-yl] -1h-quinolin-2-one for use in the treatment of adenocystic carcinoma
EA201200618A1 (en) CHROMENON DERIVATIVES WITH ANTI-TUMOR ACTIVITY
EA201390347A1 (en) TREATMENT OF DISEASES
BR112015004499A2 (en) Pirfenidone therapy administration methods
EA201100358A1 (en) DABIGATRAN FOR INTERTEGUAL SURGICAL CATHETERIZATION OF THE HEART
MX2018004328A (en) Stabilizing camptothecin pharmaceutical compositions.
MX2012007875A (en) Treatment method.
PH12014501278A1 (en) Kinase inhibitors
EA201300423A1 (en) CRYSTALLINE CONJUGATE NALOXOL-PEG
ECSP13012847A (en) DIMALEATE OF 9- [4- (3-CHLORINE-2-FLUORO-PHENYLAMINE) -7-METOXI-QUINAZOLIN-6-ILOXI] -1,4-DIAZA-ESPIRO [5.5] UNDECAN-5-ONA, ITS USE AS A MEDICINAL PRODUCT AND HIS PREPARATION.
EA201591415A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING MULTICOMPONENT CRYSTALLINE PARTICLES, SUITABLE FOR USE IN INHALATION THERAPY
WO2014081709A3 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
MX348723B (en) Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder.
RU2011119848A (en) METHOD FOR PREVENTION OF SPIKE EDUCATION
RU2014114827A (en) APPLICATION OF 4-AMINO-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1h-benzimidazole-2-yl] -1h-quinolin-2-one for treating cancer in patients with moderate liver failure
RU2014150506A (en) VELIPARIB IN COMBINATION WITH RADIATION THERAPY OF THE WHOLE BRAIN FOR TREATING METASTASIS IN THE BRAIN
UA96488U (en) A method for treating disorders of hemovascular hemostasis in patients with ischemic heart disease
RU2012125078A (en) MEANS FOR EDUCATION OF A STRONG SCAR AND METHOD OF ITS APPLICATION
RU2011108787A (en) METHOD FOR TREATING PATIENTS WITH RED PLANE